Virtu Financial LLC Invests $68,000 in Puma Biotechnology, Inc. (NASDAQ:PBYI)

Virtu Financial LLC acquired a new stake in Puma Biotechnology, Inc. (NASDAQ:PBYI) in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 26,509 shares of the biopharmaceutical company’s stock, valued at approximately $68,000. Virtu Financial LLC owned about 0.05% of Puma Biotechnology at the end of the most recent quarter.

Other hedge funds and other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC acquired a new stake in Puma Biotechnology in the third quarter valued at $34,000. Dynamic Technology Lab Private Ltd bought a new stake in shares of Puma Biotechnology in the 3rd quarter valued at about $44,000. Patriot Financial Group Insurance Agency LLC lifted its stake in Puma Biotechnology by 72.7% in the 3rd quarter. Patriot Financial Group Insurance Agency LLC now owns 19,000 shares of the biopharmaceutical company’s stock valued at $48,000 after purchasing an additional 8,000 shares during the last quarter. Royce & Associates LP grew its holdings in Puma Biotechnology by 71.8% during the third quarter. Royce & Associates LP now owns 20,165 shares of the biopharmaceutical company’s stock worth $51,000 after purchasing an additional 8,427 shares during the period. Finally, Victory Capital Management Inc. acquired a new position in Puma Biotechnology during the second quarter worth approximately $54,000. 61.29% of the stock is owned by institutional investors.

Puma Biotechnology Stock Down 1.1 %

Shares of PBYI opened at $2.75 on Friday. The firm has a market cap of $134.99 million, a P/E ratio of 5.73 and a beta of 1.08. The company has a debt-to-equity ratio of 0.46, a quick ratio of 1.40 and a current ratio of 1.42. Puma Biotechnology, Inc. has a 52 week low of $2.22 and a 52 week high of $7.73. The firm’s 50-day simple moving average is $2.95 and its 200 day simple moving average is $3.00.

Puma Biotechnology (NASDAQ:PBYI) last posted its earnings results on Thursday, November 7th. The biopharmaceutical company reported $0.41 EPS for the quarter, beating the consensus estimate of $0.31 by $0.10. The company had revenue of $80.50 million for the quarter, compared to the consensus estimate of $71.32 million. Puma Biotechnology had a return on equity of 41.60% and a net margin of 9.56%. During the same quarter in the prior year, the business earned $0.12 earnings per share. On average, analysts forecast that Puma Biotechnology, Inc. will post 0.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on PBYI shares. HC Wainwright reaffirmed a “buy” rating and issued a $7.00 price objective on shares of Puma Biotechnology in a research report on Wednesday, November 20th. StockNews.com downgraded Puma Biotechnology from a “strong-buy” rating to a “buy” rating in a report on Friday, December 6th.

About Puma Biotechnology

Puma Biotechnology, Inc, a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine.